Meitheal Pharmaceuticals said Thursday it launched a generic form of Bristol-Myers Squibb's (BMY) Abraxane in the US via an exclusive license and supply agreement with parent Hong Kong King-Friend Industry.
The single-dose protein-bound paclitaxel for injectable suspension is used to treat cancers, including metastatic breast and non-small cell lung cancers, the company said.
Price: 47.45, Change: +0.48, Percent Change: +1.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.